

1 Perceived barriers and facilitators to implementing preventive  
2 therapy for tuberculosis in Malaysian prisons: Perspectives from  
3 prison personnel

4 Phoebe Chen<sup>1</sup>, Frederick Altice<sup>2,3</sup>, Divya Ghoshal<sup>4</sup>, Ahsan Ahmad<sup>2,3</sup>, Jiang Long<sup>1,5</sup>,

5 Rumana Saifi<sup>3</sup>, Hui Moon Koh<sup>6</sup>, Naga Nagadevi<sup>3</sup>, Mohd Norbayusri Baharudin<sup>7</sup>, Esther

6 Wong Min Fui<sup>8</sup>, Adeeba Kamarulzaman<sup>2,3</sup>, Sheela Shenoi<sup>2,3\*</sup>

7 <sup>1</sup> Yale School of Medicine, New Haven, Connecticut, United States of America

8 <sup>2</sup> Yale School of Medicine AIDS Program, Section of Infectious Diseases, Yale  
9 University, New Haven, Connecticut, United States of America

10 <sup>3</sup> CERIA Center of Excellence for Research in AIDS (CERIA), Universiti Malaya, Kuala  
11 Lumpur, Malaysia

12 <sup>4</sup> Kansas City University College of Osteopathic Medicine, Kansas City, Missouri,  
13 United States of America

14 <sup>5</sup> Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine,  
15 Shanghai, China

16 <sup>6</sup> Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur,  
17 Malaysia

18 <sup>7</sup> Department of Social Administration and Justice, Faculty of Arts and Social Science,  
19 Universiti Malaya, Kuala Lumpur

20 <sup>8</sup> Ministry of Health, Malaysia

21

22 Corresponding Author: [sheela.shenoi@yale.edu](mailto:sheela.shenoi@yale.edu)

23 **Short title (70 characters):** Barriers and facilitators to initiating TPT in Malaysian

24 Prisons

25 **Disclosures:**

26 SS's spouse worked for Merck pharmaceuticals 1997-2007 and retains company stock  
27 in his retirement account. There is no conflict of interest, but it is included in the interest  
28 of full disclosure.

29 **Keywords:**

30 Tuberculosis; prevention; prison; health care workers; nominal group technique

31

32

### 33 **Abstract**

34 Tuberculosis (TB) is a major health threat worldwide. TB is concentrated in prisons,  
35 where TB preventive therapy (TPT) implementation has been limited. Prisons generally,  
36 and especially in Malaysia, are overcrowded, minimally resourced, and have high  
37 prevalence of latent TB.

38 As prison personnel are largely responsible for TPT implementation, their perspectives  
39 were sought to identify barriers and potential solutions for implementing TPT in  
40 Malaysia's largest prison. A focus group using nominal group technique (NGT) was  
41 conducted with 9 prison officers with experience related to TPT to generate a list and  
42 rank-order the top TPT barriers. The process was repeated to assess facilitators.

43 The top three barriers to implementing TPT were: 1) disruptions involved in prison  
44 activities (e.g., intra- and extra-prison transfers; 8 votes); 2) insufficient workforce (5  
45 votes), and unanticipated inter-prison transfers (4 votes). Potential solutions included  
46 implementing care coordination protocols between officers and medical staff (8 votes),  
47 placing a medical hold until TPT completion (5 votes), and improving medication  
48 delivery logistics (4 votes). All prison officers supported a short-course TPT regimen  
49 administered once-weekly for 12 weeks (i.e. rifapentine and isoniazid (3HP)), over a  
50 daily TPT regimen for 6 months (i.e. isoniazid (26H)), due to less logistics and staff time  
51 required.

52 From the perspective of prison officer stakeholders, logistical constraints commonly  
53 observed in prisons were perceived to impact the implementation of TPT, yet they  
54 prioritized pragmatic solutions that align with known implementation strategies to  
55 employ to optimize TPT delivery, including developing stakeholder relationships

56 between medical and prison personnel and changing infrastructure to address frequent  
57 transfers within and between prisons and the community.

58

## 59 **Introduction:**

60 Tuberculosis (TB) is the world's second deadliest infectious disease, second only to  
61 COVID-19, despite the existence of highly effective treatment and preventive therapies  
62 [1]. A quarter of the global population is estimated to have latent TB infection (LTBI) and  
63 are at risk of developing active TB disease [2]. TB disproportionately impacts  
64 incarcerated populations, who have a disease burden ten times higher than the general  
65 population [3], due to factors like overcrowding, malnutrition, and delayed diagnosis [4].  
66 In Malaysia, over a quarter of the population has LTBI [5], with significantly higher  
67 prevalence in Malaysian prisons (68% to 88%), as identified previously [6–8]. TB  
68 prevalence is concentrated in prisons and complicated by overcrowding, punitive drug  
69 policies, and limited prison resources [4,9]. Structural challenges to TB control in  
70 prisons include vulnerable and marginalized populations pre-disposed to high TB risk,  
71 inadequate ventilation, poor nutrition, comorbid substance use, and poor access to  
72 medical care [10]. Periods of incarceration thus present an opportunity to intervene in  
73 the TB epidemic by targeting vulnerable individuals during a critical time period of  
74 heightened risk [11]. Even though controlling communicable diseases, including TB,  
75 among incarcerated persons is included in Malaysian prison regulations [12], prison  
76 management faces difficulties in controlling the disease in the high risk prison  
77 environment, hence impacting institutions and creating pressures on treatment quality,  
78 incident risk, and health of both staff and incarcerated persons [13].

79 TB preventive therapy (TPT) is a safe, highly efficacious, and cost-effective method to  
80 prevent the progression of latent TB infection (LTBI) to active TB disease [2]. TPT is  
81 one of the key pillars of WHO's End TB Strategy to control the worldwide TB epidemic  
82 [2]. In 2018, at the UN High-Level Meeting on TB, all country leaders pledged to provide  
83 TPT to at least 30 million people at risk of progression to TB disease by 2022; however,  
84 only 15.5 million people received TPT between 2018 and 2022 [3]. Despite advances in  
85 shorter and better tolerated TPT regimens and reduced costs, TPT remains  
86 underutilized globally [14]. The WHO considers the scale-up of TPT to be critical to the  
87 End TB Strategy, and UN leaders recently pledged to provide TPT to 45 million people  
88 by 2027 [15]. Challenges to scaling up TPT include poor program performance in  
89 identifying opportunities to test and treat target populations, limited uptake of shorter  
90 TPT regimens, and cost [15,16]. TPT remains unavailable in most prisons, despite a  
91 strong case for implementation in this high risk and high prevalence setting. As of 2023,  
92 the TB burden in prisons is substantial and growing globally [14]. Prisons serve as  
93 important reservoirs for TB, including multi-drug-resistant (MDR) TB, which is  
94 transmitted to the general population through the prison workforce and release of  
95 incarcerated persons [11,17–19].

96 To scale up TPT in prisons, a better understanding of the implementation context is  
97 required. To date, there is limited research informing TPT implementation in low- and  
98 middle-income countries (LMICs), particularly within prisons [17,20–24]. It is difficult to  
99 implement TPT in the prison environment without relevant stakeholder input on context  
100 and facilitators. Therefore, it is crucial to obtain insights from prison staff who would  
101 administer and coordinate TPT initiatives. This study elicited prison officers'

102 perspectives on TPT barriers and facilitators in Malaysia's largest prison, which was  
103 vital to filling in the evidence gap using an established implementation framework.

#### 104 **Methods**

105 To understand the barriers to implementing TPT in prisons in Malaysia, we used the  
106 established Practical Robust Implementation and Sustainability Model (PRISM), which  
107 expands the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM)  
108 framework to identify contextual factors to guide our pre-implementation process. Since  
109 multiple factors may influence TPT implementation, we examined the inner context by  
110 interviewing prison officers who are key implementers and can either impede or  
111 promote TPT adoption and implementation. In Malaysia, the prevalence of latent TB  
112 among prison officers is approximately 81%, as high as it is for people in prison, making  
113 prisons a high-risk environment to anyone in this setting [25]. As such, they are key  
114 stakeholders for whether and how TPT is implemented.

#### 115 **Participants and Setting**

116 In July 2023, we recruited 10 participants from Malaysia's largest prison near Kuala  
117 Lumpur using purposive sampling. The prison director introduced the study and invited  
118 10 prison officers to participate. Eligibility included employment at the prison for at least  
119 6 months and had direct experience interfacing with medical staff and assisting with  
120 medication administration. Prison officers had no formal TB or TPT training, though they  
121 possessed a basic understanding of TB informally passed on from prison medical staff.  
122 The study was voluntary and conducted in a private room outside the prison with one  
123 facilitator and one translator for English and Bahasa Malaysia. One participant

124 generated ideas but had to leave before voting, leaving 9 participants who contributed  
125 data to the rank-ordering.

126 Kajang Prison houses over 5000 incarcerated persons [26] and is overcrowded, making  
127 incarcerated persons vulnerable to TB infection. The medical unit employs 4  
128 physicians and 6 medical assistants, with a doctor to patient ratio of 1:1250. All persons  
129 newly-admitted to prison undergo screening for HIV; while national guidelines also  
130 recommend screening for TB, implementation lags [27]. If a person has symptoms  
131 observed by a prison officer or healthcare provider, they are isolated, evaluated, and, if  
132 testing positive for active TB, initiated on treatment at a nearby government hospital,  
133 with the remainder of treatment to be completed in the prison. There is no standardized  
134 protocol for medication administration across prisons. In Kajang prison, the prison  
135 officer collects medication from the medical clinic and is responsible for administering  
136 daily observed therapy in the TB housing unit. TPT is not currently deployed.

### 137 **Procedures**

138 Participants completed a brief survey prior to the session and provided verbal consent  
139 and were reminded that the discussion was confidential. No compensation was  
140 provided. The study protocol was approved by the Institutional Review Boards at Yale  
141 University (#2000020053) and the Universiti Malaya (#17-19-33974), and the Medical  
142 Research & Ethics Committee (MREC) at the Malaysian Ministry of Health (#NMRR ID-  
143 17-19-33974), with approval from the Malaysian Prison's Department.  
144 The focus group was conducted using nominal group technique (NGT). The expert  
145 facilitator interacted with participants while research assistants took notes and recorded

146 responses on a whiteboard for all participants to observe. The session was audio-  
147 recorded, transcribed, and translated.

148 NGT is a well-established mixed-methods strategy increasingly used in implementation  
149 research to rapidly identify barriers and solutions for health service delivery [27–31]. We  
150 chose NGT to obtain both quantitative estimates of priority (rank-ordering) and in-depth  
151 qualitative information that could be rapidly implemented. Compared to traditional focus  
152 groups, NGT also ensures more equitable participation from all participants. The NGT  
153 process was as follows: (a) silent generation of ideas in response to the initial question  
154 “What gets in the way of prisoners receiving medications to prevent TB every day for 6  
155 months?”; (b) round-robin feedback from participants where each participant contributed  
156 a single idea on a whiteboard until saturation was reached; (c) clarification of ideas as  
157 needed by the moderator, allowing for structured group discussion and evaluation of  
158 ideas; some ideas were grouped together by consensus and duplicate items were  
159 removed; and (d) individual voting, with each participant allocating up to 3 votes to  
160 idea(s) they deemed most important. Votes were tallied and the group decision was  
161 mathematically derived through rank-ordering [27]. The facilitator led a final discussion  
162 to review the participants’ results and ensure that they had face validity among  
163 participants. This process was repeated with the second question “What could you do or  
164 what would be needed to fix these problems that get in the way?” to elicit proposed  
165 solutions based on the top-3 ranked barriers. Last, the facilitator proposed a new idea to  
166 “Change to a weekly (not daily medication) for TPT” and asked participants with this  
167 new information, how many of their 3 votes, if any, they would re-allocate to this idea.



168 Focus group questions were based on prior literature and experts in TB treatment, NGT  
169 methodology, and prison health.

## 170 **Results:**

### 171 **Demographics**

172 All participants (n=10) were male prison officers whose mean age was 32.7 years and  
173 had worked as a prison officer for a mean of 8.6 years. Nine respondents (90%) voted  
174 on both questions. 1 participant contributed to the discussion but left prior to the first  
175 round of voting due to urgent prison duties.

### 176 **Perceived Barriers**

177 **Table 1** presents perceived barriers to implementing TPT in the Malaysian prison  
178 setting. The top three barriers to TPT delivery were interruptions to the routine prison  
179 schedule (8 votes), including transfers within the prison and to outside appointments  
180 (e.g. due to court cases, hospital visits, transfers within prison housing units), limited  
181 prison staff to ensure TPT delivery (5 votes), and unanticipated transfer to another  
182 prison (4 votes). The remaining barriers are listed in Table 1.

### 183 **Table 1: Key barriers for implementing TPT in prison (N=9)**

Votes	Perceived Barriers
8	Interruptions in prison schedule (e.g. court cases, hospital)
5	Staff too busy – limited workforce
4	Patient is transferred to another prison
3	Released from prison (home, early, parole)
2	Transfer to another prison housing unit (officers don't know where the patient is)
2	Medical clinic does not provide meds on time
1	Security concerns (less access in high security)
1	Can't find the patient - locate

- 1 Patient has a side effect
- 0 Prisoner does not inform officer with transfer
- 0 Patient dies
- 0 Patient refuses to take it

184

## 185 **Perceived Facilitators**

186 Table 2 presents perceived facilitators for the 3 main barriers identified. The top three  
187 solutions were improving care coordination between prison officers and medical staff to  
188 ensure continued medication delivery when schedule disruptions occurred (8 votes),  
189 deploying a medical hold to avoid transferring the patient until TPT was completed (5  
190 votes), and moving medications closer to patient housing units with a supply of  
191 medication at each prison housing unit (4 votes). The remaining facilitators are listed in  
192 Table 2.

### 193 **Table 2: Key perceived facilitators for initiating TPT in prison**

Votes	Perceived Facilitators
8	Coordinate b/t officers and medical staff before transfer, release, or court case
5	Use a medical hold until treatment completed
4	Move the storage of medications to housing unit
3	Officer must check to see if prisoner is on medication before they are released
3	Education for officers re: TB adherence
3	Segregate patients in special treatment unit near medical clinic
1	Train a current officer to be in charge on all TB medications

194

195 Finally, when presented with an option at the end of the NGT session to “Change to a  
196 weekly (not daily medication)”, participants re-allocated 19 votes of 27 votes to this  
197 option. The majority of participants expressed this change would dramatically improve  
198 adherence and maximize use of their limited human resources.

## 199 **Discussion**

200 As Malaysia struggles to control its TB epidemic in a country with high TB burden, it is  
201 crucial to target TPT to those most vulnerable and accessible – to people in prison  
202 where TB prevalence is extraordinarily high (68% to 88%) [6–8]. There have been  
203 recent calls for accelerated strategies to screen for TB [10] and to introduce TPT in  
204 prisons [14], yet guidelines on how to best deliver TPT in this setting require tailoring to  
205 each context [32].

206 In the absence of clear guidelines for TPT delivery in prisons, the PRISM/RE-AIM  
207 framework provides an ideal heuristic for pre-implementation assessment to guide  
208 future implementation. Though people in prison are the major target for TPT, their  
209 access to treatment can be hindered or facilitated by multiple stakeholders, including  
210 prison medical staff and custodial staff. We used this framework to prepare for a future  
211 TPT implementation program in prisons, and, in collaboration with prison officer  
212 stakeholders, explore potential implementation strategies based on themes prioritized  
213 by prison personnel [33–37].

214 Though many of the barriers and facilitators to TPT may be common in prisons, it is  
215 important to tailor implementation to context. For example, in Malaysia, prison turnover  
216 has substantially increased with shortened stays in prison and multiple disruptions with  
217 transfers between housing units, prisons and to the community either for court  
218 appearances or medical appointments at government hospitals or release to home.

219 Important here is that the prison officers were unaware of newer TPT options like 3  
220 months of once-weekly isoniazid plus rifapentine (3HP). They perceived that switching

221 to this strategy rather than the standard 6 months of daily isoniazid preventive therapy  
222 (IPT) would minimize disruptions in medication delivery due to typical and sometimes  
223 unexpected logistical transfers. This short-course regimen with less frequent dosing has  
224 higher acceptability and completion rates relative to IPT and may be especially useful in  
225 prisons where high turnover logistical barriers undermine treatment completion  
226 (14,17,20,22,37). Recent TPT programs in prisons in Thailand and Pakistan achieved  
227 87-93% completion rates [20,21]. A prior systematic review of 6-month IPT completion  
228 rates in prisons was substantially lower at 44%, reducing the enthusiasm for such a  
229 strategy by international agencies [17]. Cited barriers by prison personnel was the  
230 shortage of staff, insufficient knowledge and training, and a lack of prioritization for  
231 prison health and resources by governmental authorities [38,39], which might partially  
232 be solved by a once-weekly, 3HP short-course therapy that would reduce work  
233 demands on staff and minimize security demands by minimizing movement by people in  
234 prison. In addition, re-entry to the community and prison transfers are known high-risk  
235 events for interruption in TB care.

### 236 **Develop stakeholder inter-relationships**

237 In the absence of a 3HP strategy, prison officers' top suggestion to optimize TPT was to  
238 enhance care coordination between prison officers and medical staff, which could be  
239 accomplished through local consensus discussions and checklists [10,23,40]. For  
240 example, prison officers could meet with medical personnel at the end of each week to  
241 discuss any anticipated transfer expected for the following week. In such cases, medical  
242 staff might try a number of approaches like prepare transfer medications to people who  
243 are moving to another prison or deliver medications the day before for offsite visits. As

244 there can be a tension between medical and custodial staff in terms of prioritizing health  
245 vs security, creating a shared vision for creating a safe environment to minimize TB  
246 transmission to personnel might align their missions. This is especially true in places  
247 like Malaysia where in the absence of such a shared mission, prison personnel have  
248 latent TB infection rates similar to people in prison due to a shared risk environment  
249 [25].

### 250 **Change infrastructure**

251 The second-ranked implementation strategy supported by prison officers was to change  
252 prison infrastructure to minimize disruptions due to transfers. Key among them, which  
253 has been done in other prison settings, is to ensure that the TPT medications are closer  
254 to housing units. instead of at the medical clinic, and provision of a temporary  
255 medication supply accompanying the patient during transfers or release to finish their  
256 treatment course. Though they did not provide specifics, this infrastructure change  
257 might include the entire week's supply of medication being delivered to the housing unit  
258 for dispensation, or in the case of daily observed therapy, having the medical staff make  
259 daily deliveries to the housing unit rather than rely on a traditional "roll call" where  
260 people in prison must leave their units to receive medications at the medical unit. An  
261 alternative, but equally important suggestion was to have the custodial staff institute a  
262 "medical hold" for any patients prescribed TPT, which would prevent such persons from  
263 any kind of transfer until there was secondary clearance by a medical officer.

### 264 **Training and Education**

265 Though identified as a lower priority, prison officers also identified the need for more  
266 trainings and knowledge about TB and TPT. Such a strategy could have benefits that  
267 include creating a shared vision of reducing the risk for TB transmission to prison  
268 personnel, but also to reduce TB incidence nationally in Malaysia. In many prisons,  
269 including in Malaysia, only prison medical staff receive TB training from the Ministry of  
270 Health. These trainings emphasize active TB and do not adequately address latent TB  
271 or TPT. Unilateral training undermines any shared alignment for ensuring TPT. Formal  
272 comprehensive training and knowledge-sharing on TB and TPT between medical and  
273 non-medical prison staff could bridge the knowledge gap and emphasize the importance  
274 of TPT and medication adherence to all personnel. In low-resource settings, educational  
275 meetings and training workshops have strong evidence for improving patient outcomes.  
276 For example, in Thai prisons, high health literacy among prison officers was associated  
277 with good TB practices [42,43]. The U.S. Centers for Disease Control and Prevention  
278 (CDC) also recommends all correctional officers in high risk facilities receive TB training  
279 [43]. Further data are needed on knowledge level of TB and TPT and training needs for  
280 prison staff but should be explored further.

281 Of interest here is the lack of discussion or prioritization of other key stakeholder  
282 relationships that might influence TPT delivery, like with the Ministry of Health and  
283 prison leadership. Political will is crucial for a successful response to TB  
284 in prisons [11,24,40]. This political will not only requires executive sponsorship from  
285 leadership, but also a financial commitment to prioritize TPT implementation in prisons  
286 [40]. In the case of prisons, it often requires a joint commitment by both the Ministry of  
287 Justice (or sometimes Interior) and Ministry of Health and unless both are fully

288 committed to prioritize TB control, then implementation efforts might not be fully  
289 optimized. Stakeholder engagement and consensus-building will be important to bridge  
290 conflicting priorities for criminal justice (security) and public health (prevention and  
291 treatment) [11,40]. Such aligned engagement would be crucial to optimizing the national  
292 budget for TB and ensure that a proportionate amount is allocated to TB control in  
293 prisons. Given the limited amount of funding allocated to prisons and health, blended  
294 implementation strategies that include a combination of low threshold strategies like  
295 education and infrastructure changes as suggested by the officers may be low cost,  
296 though care coordination and evaluative and iterative strategies may be needed to  
297 change day-to-day operations. Such examples can include audit and feedback to  
298 ensure that all people who enter prisons are screened for latent TB infection, and if  
299 diagnosed, that there are methods to track TPT initiation and adherence to treatment.  
300 This might involve creation of checklists to diagnose latent TB infection or dashboards  
301 that track the number of people on treatment and notifying prison officers of adherence  
302 rates with real-time feedback cycles.

### 303 **Study Limitations**

304 While there are many important and pragmatic perspectives listed and ranked by prison  
305 officers, this sample represents only one stakeholder group - the prison officers who  
306 control the movement of people in prison. As such, they represent one important  
307 gatekeeper to implementing TPT. Their perspective should be reviewed and  
308 triangulated with other stakeholders as was done recently when identifying and  
309 prioritizing barriers to implementing syringe services programs in prison in Canada

310 [29,44]. Future studies also need to involve other stakeholders, like clinicians in prison  
311 people in prison, and outer context authorities.

312 While a single NGT session might be insufficient to be fully representative or achieve  
313 saturation, the findings here have face validity and accurately represent known barriers.  
314 Their solutions, however, might represent an initial plan to select and prioritize  
315 implementation strategies and follow-up NGT could be done to determine if the  
316 observed barriers were successfully overcome.

317 Lastly, while the barriers and facilitators represent the perception by the officers, they  
318 may not be fully accurate. For example, in this session, a substantial number of officers  
319 changed their vote after learning about an innovative TPT strategy – a 3-month TPT  
320 regimen that requires administration only once per week. Thus, in the absence of being  
321 informed by ideas outside the prison, their selection of implementation strategies may  
322 not fully align with all the true possibilities. Notwithstanding these limitations, the ideas  
323 generated provide a heuristic for implementing actionable changes to optimize TPT  
324 delivery in Malaysian prisons.

## 325 **Conclusions**

326 Despite several decades of TPT and strong evidence supporting its efficacy,  
327 implementation of TPT in prisons has been limited with challenges in adherence and  
328 completion rates. However, prisons are sentinel sites for TB reactivation, transmission,  
329 and development of MDR TB with dire public health consequences. Prioritizing more  
330 stakeholder engagement, changes to infrastructure and logistical processes, and  
331 resources to optimize TPT implementation in prisons may greatly improve TB control. In



332 the future, this pre-implementation framework may be a useful model for other prisons  
333 in Malaysia and other low-resource settings.

### 334 **Acknowledgements**

335 We appreciate support for this project from the Malaysian Ministry of Health, Prisons  
336 Department, and Centre of Excellence for Research in AIDS, University Malaya.

### 337 **References**

- 338 1. The top 10 causes of death. WHO. 2024 [cited 29 Aug 2024]. Available:  
339 <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>
- 340 2. Implementing the end TB strategy: the essentials, 2022 update. WHO; 2022 Dec.  
341 Available: <https://www.who.int/publications/i/item/9789240065093>
- 342 3. Global tuberculosis report 2023. Geneva; 2023. Available:  
343 <https://www.who.int/publications/i/item/9789240083851>
- 344 4. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al.  
345 Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.  
346 *Lancet*. 2016;388: 1089–1102. doi:10.1016/S0140-6736(16)30466-4
- 347 5. Ding C, Hu M, Guo W, Hu W, Li X, Wang S, et al. Prevalence trends of latent  
348 tuberculosis infection at the global, regional, and country levels from 1990–2019.  
349 *International Journal of Infectious Diseases*. 2022;122: 46–62.  
350 doi:10.1016/j.ijid.2022.05.029
- 351 6. Al-Darraji HAA, Kamarulzaman A, Altice FL. Latent tuberculosis infection in a  
352 Malaysian prison: implications for a comprehensive integrated control program in  
353 prisons. *BMC Public Health*. 2014;14: 22. doi:10.1186/1471-2458-14-22
- 354 7. Zhang L, Shenoi S, Kamarulzaman A, Dhaliwal S, Ahmad A, Altice F. High  
355 Prevalence of Latent Tuberculosis Infection in a Malaysian Prison. *Open Forum*  
356 *Infectious Diseases*. 2023;10. doi:10.1093/ofid/ofad500.1729
- 357 8. Margolis B, Al-Darraji HAA, Wickersham JA, Kamarulzaman A, Altice FL.  
358 Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners  
359 in northeastern Malaysia. *The International Journal of Tuberculosis and Lung Disease*.  
360 2013;17: 1538–1544. doi:10.5588/ijtld.13.0193

- 361 9. Ahmad A, Kamarulzaman A, Kazatchkine M, Dreifuss R, Clark H. The 67th UN  
362 CND—upholding human rights in drug policy. *The Lancet*. 2024;403: 1851–1852.  
363 doi:10.1016/S0140-6736(24)00763-3
- 364 10. Charalambous S, Velen K, Rueda Z, Croda J, Herce ME, Shenoi SV, et al.  
365 Scaling up evidence-based approaches to tuberculosis screening in prisons. *The Lancet*  
366 *Public Health*. 2023;8: e305–e310. doi:10.1016/S2468-2667(23)00002-6
- 367 11. Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et  
368 al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and  
369 tuberculosis in prisoners. *Lancet*. 2016;388: 1115–1126. doi:10.1016/S0140-  
370 6736(16)30769-3
- 371 12. Laws of Malaysia. (2000). *Peraturan-peraturan Penjara 2000*. The Commissioner  
372 of Law Revision, Malaysia.
- 373 13. Baharudin MN, Mohamad M, Karim F. Drug-abuse inmates maqasid shariah  
374 quality of life: a conceptual paper. *Humanities & Social Sciences Reviews*. [cited 17 Jul  
375 2024]. doi:<https://doi.org/10.18510/hssr.2020.83131>
- 376 14. Narayan A, Salindri AD, Keshavjee S, Muyoyeta M, Velen K, Rueda ZV, et al.  
377 Prioritizing persons deprived of liberty in global guidelines for tuberculosis preventive  
378 treatment. *PLoS Med*. 2023;20: e1004288. doi:10.1371/journal.pmed.1004288
- 379 15. Tuberculosis preventive treatment: rapid communication. [cited 26 Jun 2024].  
380 Available: <https://www.who.int/publications/i/item/9789240089723>
- 381 16. Bhargava A. The 3 HP regimen for tuberculosis preventive treatment: safety,  
382 dosage and related concerns during its large-scale implementation in countries like  
383 India. *The Lancet Regional Health - Southeast Asia*. 2024;0.  
384 doi:10.1016/j.lansea.2024.100422
- 385 17. Al-Darraji HAA, Kamarulzaman A, Altice FL. Isoniazid preventive therapy in  
386 correctional facilities: a systematic review. *The International Journal of Tuberculosis and*  
387 *Lung Disease*. 2012;16: 871–879. doi:10.5588/ijtld.11.0447
- 388 18. Warren JL, Grandjean L, Moore DAJ, Lithgow A, Coronel J, Sheen P, et al.  
389 Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and  
390 molecular epidemiological analysis. *BMC Med*. 2018;16: 122. doi:10.1186/s12916-018-  
391 1111-x
- 392 19. Gygli SM, Loiseau C, Jugheli L, Adamia N, Trauner A, Reinhard M, et al. Prisons  
393 as ecological drivers of fitness-compensated multidrug-resistant *Mycobacterium*  
394 tuberculosis. *Nat Med*. 2021;27: 1171–1177. doi:10.1038/s41591-021-01358-x

- 395 20. Mapingure MP, Zech JM, Hirsch-Moverman Y, Msukwa M, Howard AA, Makoni  
396 T, et al. Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast  
397 Track HIV treatment model: experiences from a pilot study. *Journal of the International*  
398 *AIDS Society*. 2023;26: e26105. doi:10.1002/jia2.26105
- 399 21. Gatechompol S, Harnpariphan W, Supanan R, Suwanpimolkul G, Sophonphan J,  
400 Ubolyam S, et al. Prevalence of latent tuberculosis infection and feasibility of TB  
401 preventive therapy among Thai prisoners: a cross-sectional study. *BMC Public Health*.  
402 2021;21: 1206. doi:10.1186/s12889-021-11271-0
- 403 22. Chimoyi L, Smith H, Hausler H, Fielding K, Hoffmann CJ, Hecce ME, et al.  
404 Delivery of TB preventive therapy to incarcerated people living with HIV in southern  
405 African correctional facilities. *Public Health Action*. 2021;11: 171–173.  
406 doi:10.5588/pha.21.0056
- 407 23. Aguiar A, Abreu M, Duarte R. Healthcare professionals perspectives on  
408 tuberculosis barriers in Portuguese prisons—a qualitative study. *Journal of Public*  
409 *Health*. 2024; fdae065. doi:10.1093/pubmed/fdae065
- 410 24. Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Sheno SV. Structural  
411 barriers to implementing recommended tuberculosis preventive treatment in primary  
412 care clinics in rural South Africa. *Glob Public Health*. 2022;17: 555–568.  
413 doi:10.1080/17441692.2021.1892793
- 414 25. Al-Darraj HAA, Tan C, Kamarulzaman A, Altice FL. Prevalence and correlates of  
415 latent tuberculosis infection among employees of a high security prison in Malaysia.  
416 *Occup Environ Med*. 2015;72: 442–447. doi:10.1136/oemed-2014-102695
- 417 26. Security & Intelligence Division, Malaysian Prison Department (2024). *Lokaliti*  
418 *Penjara Semasa*.
- 419 27. *Guidelines for Tuberculosis Control in Prison Institutions in Malaysia*. Ministry of  
420 Health, Malaysia; 2017.
- 421 28. Madden L, Bojko MJ, Farnum S, Mazhnaya A, Fomenko T, Marcus R, et al.  
422 Using nominal group technique among clinical providers to identify barriers and  
423 prioritize solutions to scaling up opioid agonist therapies in Ukraine. *Int J Drug Policy*.  
424 2017;49: 48–53. doi:10.1016/j.drugpo.2017.07.025
- 425 29. DiDomizio E, Chandra DK, Nichols L, Villanueva M, Altice FL. Challenges to  
426 Achieving HCV Micro-Elimination in People With HIV in the United States: Provider  
427 Perspectives and the Role of Implicit Bias. *Health Promot Pract*. 2023;24: 998–1008.  
428 doi:10.1177/15248399231169928

- 429 30. Kronfli N, Lafferty L, Leone F, Stoové M, Hajarizadeh B, Lloyd AR, et al. Using  
430 nominal group technique to identify perceived barriers and facilitators to improving  
431 uptake of the Prison Needle Exchange Program in Canadian federal prisons by  
432 correctional officers and healthcare workers. *Int J Drug Policy*. 2024;130: 104540.  
433 doi:10.1016/j.drugpo.2024.104540
- 434 31. Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using  
435 nominal group technique to identify barriers, facilitators, and preferences among  
436 patients seeking treatment for opioid use disorder: A needs assessment for decision  
437 making support. *J Subst Abuse Treat*. 2019;100: 18–28. doi:10.1016/j.jsat.2019.01.019
- 438 32. Rosen AO, Wickersham JA, Altice FL, Khati A, Azwa I, Tee V, et al. Barriers and  
439 Facilitators to Pre-Exposure Prophylaxis by Men Who Have Sex with Men and  
440 Community Stakeholders in Malaysia. *Int J Environ Res Public Health*. 2023;20: 5669.  
441 doi:10.3390/ijerph20095669
- 442 33. Isoniazid vs. 3HP: treatment completion and adverse events in a RCT conducted  
443 in the largest prison in Malaysia. *The Union World Conference on Lung Health 2024*;  
444 2024 Nov; Bali.
- 445 34. Waltz TJ, Powell BJ, Matthieu MM, Damschroder LJ, Chinman MJ, Smith JL, et  
446 al. Use of concept mapping to characterize relationships among implementation  
447 strategies and assess their feasibility and importance: results from the Expert  
448 Recommendations for Implementing Change (ERIC) study. *Implementation Science*.  
449 2015;10: 109. doi:10.1186/s13012-015-0295-0
- 450 35. Kirchner, J. E., Waltz, T. J., Powell, B. J., Smith, J. L., & Proctor, E. K. RC.  
451 Implementation strategies. *Dissemination and Implementation Research in Health*. 2nd  
452 ed. 2018.
- 453 36. Lovero KL, Kemp CG, Wagenaar BH, Giusto A, Greene MC, Powell BJ, et al.  
454 Application of the Expert Recommendations for Implementing Change (ERIC)  
455 compilation of strategies to health intervention implementation in low- and middle-  
456 income countries: a systematic review. *Implementation Science*. 2023;18: 56.  
457 doi:10.1186/s13012-023-01310-2
- 458 37. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et  
459 al. A refined compilation of implementation strategies: results from the Expert  
460 Recommendations for Implementing Change (ERIC) project. *Implementation Science*.  
461 2015;10: 21. doi:10.1186/s13012-015-0209-1
- 462 38. Yakovchenko V, Chinman MJ, Lamorte C, Powell BJ, Waltz TJ, Merante M, et al.  
463 Refining Expert Recommendations for Implementing Change (ERIC) strategy surveys

- 464 using cognitive interviews with frontline providers. *Implementation Science*  
465 *Communications*. 2023;4: 42. doi:10.1186/s43058-023-00409-3
- 466 39. Hinduan ZR, Suherman H, Pinxten WJL, Alisjahbana B, Hospers HJ. HIV-related  
467 knowledge and attitudes among Indonesian prison officers. *Int J Prison Health*. 2013;9:  
468 92–102. doi:10.1108/17449201311326961
- 469 40. Rosen DL, Blue C, Brown M, Bradley-Bull S, DiRosa EA, Carda-Auten J. The  
470 role of detention officers in the provision of jail healthcare in the Southeastern United  
471 States. *Soc Sci Med*. 2023;330: 116065. doi:10.1016/j.socscimed.2023.116065
- 472 41. Dara M, Acosta CD, Melchers NVSV, Al-Darraji HAA, Chorgoliani D, Reyes H, et  
473 al. Tuberculosis control in prisons: current situation and research gaps. *Int J Infect Dis*.  
474 2015;32: 111–117. doi:10.1016/j.ijid.2014.12.029
- 475 42. Pantoja T, Opiyo N, Lewin S, Paulsen E, Ciapponi A, Wiysonge CS, et al.  
476 Implementation strategies for health systems in low-income countries: an overview of  
477 systematic reviews. *Cochrane Database Syst Rev*. 2017;2017: CD011086.  
478 doi:10.1002/14651858.CD011086.pub2
- 479 43. Rakpaitoon S, Thanapop S, Thanapop C. Correctional Officers' Health Literacy  
480 and Practices for Pulmonary Tuberculosis Prevention in Prison. *Int J Environ Res Public*  
481 *Health*. 2022;19: 11297. doi:10.3390/ijerph191811297
- 482 44. Prevention and Control of Tuberculosis in Correctional and Detention Facilities:  
483 Recommendations from CDC: Endorsed by the Advisory Council for the Elimination of  
484 Tuberculosis, the National Commission on Correctional Health Care, and the American  
485 Correctional Association. [cited 26 Jun 2024]. Available:  
486 <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5509a1.htm>
- 487 45. Lafferty L, Altice FL, Leone F, Stoové M, Lloyd AR, Hajarizadeh B, et al. Using  
488 nominal group technique with people who are incarcerated in Canadian federal prisons  
489 to identify barriers and solutions to improving Prison Needle Exchange Program uptake.  
490 *International Journal of Drug Policy*. 2024;131: 104549.  
491 doi:10.1016/j.drugpo.2024.104549
- 492